FY2018 EPS Estimates for Medgenics Inc (GNMX) Increased by Analyst

Medgenics Inc (NASDAQ:GNMX) – Analysts at Jefferies Group increased their FY2018 earnings estimates for shares of Medgenics in a research report issued on Tuesday. Jefferies Group analyst M. Andrews now expects that the biotechnology company will earn ($0.67) per share for the year, up from their previous estimate of ($0.82). Jefferies Group also issued estimates for Medgenics’ FY2019 earnings at ($1.26) EPS, FY2020 earnings at ($1.59) EPS and FY2021 earnings at ($1.35) EPS.

Shares of Medgenics (NASDAQ GNMX) traded down $0.01 during midday trading on Thursday, reaching $2.26. The company’s stock had a trading volume of 160,400 shares, compared to its average volume of 293,870. Medgenics has a 52-week low of $0.98 and a 52-week high of $6.18.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Northern Capital Management LLC boosted its stake in Medgenics by 43.6% during the 3rd quarter. Northern Capital Management LLC now owns 152,300 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 46,250 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Medgenics by 515.8% during the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 78,400 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Medgenics by 433.7% during the 3rd quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 106,178 shares in the last quarter. 16.57% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Medgenics Inc (GNMX) Increased by Analyst” was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/15/fy2018-eps-estimates-for-medgenics-inc-gnmx-increased-by-analyst.html.

Medgenics Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease.

Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply